PTGX
Protagonist Therapeutics Inc

3,362
Mkt Cap
$5.3B
Volume
297,489.00
52W High
$96.54
52W Low
$33.70
PE Ratio
133.80
PTGX Fundamentals
Price
$82.23
Prev Close
$84.75
Open
$84.51
50D MA
$85.99
Beta
0.44
Avg. Volume
941,112.14
EPS (Annual)
$4.23
P/B
8.20
Rev/Employee
$3.45M
Loading...
Loading...
News
all
press releases
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (Protagonist) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking...
Business Wire·11d ago
News Placeholder
More News
News Placeholder
Moody Aldrich Partners LLC Sells 27,510 Shares of Protagonist Therapeutics, Inc. $PTGX
Moody Aldrich Partners LLC cut its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 16.1% in the third quarter, according to the company in its most recent filing with the...
MarketBeat·15d ago
News Placeholder
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Moderate Buy" from Analysts
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fourteen research firms that are currently covering the firm...
MarketBeat·17d ago
News Placeholder
Exchange Traded Concepts LLC Sells 13,839 Shares of Protagonist Therapeutics, Inc. $PTGX
Exchange Traded Concepts LLC reduced its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 29.2% during the 3rd quarter, according to the company in its most recent...
MarketBeat·21d ago
News Placeholder
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Voya Investment Management LLC
Voya Investment Management LLC raised its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 8.9% during the third quarter, according to its most recent disclosure with the SEC...
MarketBeat·25d ago
News Placeholder
Assenagon Asset Management S.A. Decreases Stock Holdings in Protagonist Therapeutics, Inc. $PTGX
Assenagon Asset Management S.A. lowered its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 28.4% in the third quarter, according to the company in its most recent...
MarketBeat·25d ago
News Placeholder
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High - What's Next?
Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year High - Time to Buy...
MarketBeat·1mo ago
News Placeholder
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by BVF Inc. IL
BVF Inc. IL increased its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 24.7% during the second quarter, according to the company in its most recent disclosure with...
MarketBeat·1mo ago
News Placeholder
683 Capital Management LLC Reduces Stake in Protagonist Therapeutics, Inc. $PTGX
683 Capital Management LLC lowered its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 11.0% in the second quarter, according to its most recent disclosure with the...
MarketBeat·1mo ago
News Placeholder
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $803,000 Position in Protagonist Therapeutics, Inc. $PTGX
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 56.4% in the 2nd quarter, according to its...
MarketBeat·1mo ago
<
1
2
...
>

Latest PTGX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.